https://www.selleckchem.com/pr....oducts/gilteritinib-
Of 734 participants randomized, 728 received study drugs and were included in analyses. At week 96, HIV-1 RNA 50 copies/mL was achieved by 77.5% of DOR/3TC/TDF vs 73.6% of EFV/FTC/TDF participants, with a treatment difference of 3.8% (95% confidence interval, -2.4% to 10%). Virologic failure rates were low and similar across treatment arms, with no additional resistance to DOR observed between weeks 48 and 96. Prespecified neuropsychiatric adverse events and rash were less frequent in DOR/3TC/TDF than in EFV/FTC/TDF par
Like
Comment
Share
